Furthermore, MYC can serve as a therapeutic target for MAX mutated pheochromocytoma, and we can continue to study the application of MYC in NSCLC (Cascón and Robledo 2012; Massó-Vallés et al. 2020). Here, MYC is linked to hereditary pheochromocytoma-paraganglioma.